Our results established a new association between MLL2/KMT2D and MLL3/KMT2C genes with CML and suggest that MLL2/KMT2D is associated with disease evolution and may be a potential marker to predict the development of therapy resistance. Here, KMT2D is linked to chronic myelogenous leukemia, BCR-ABL1 positive.